A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer

BMC Cancer

Table 3 Prognostic potential of PCa signatures

	P-values (compared to known PCa signatures)			P-values (compared to random sets of genes)
Dataset Signature	STO	CAM	MSKCC	STO	CAM	MSKCC	Ref
CUZICK	0.00466	0.01610	2.10E-06	0.0182	0.0272	0.0000	22
TMCC11	0.00915	0.00479	0.000173	0.0305	0.0120	0.0018	This study
HES6	0.00544	0.00447	0.24900	0.0242	0.0126	0.5834	56
ROSS(100E)	0.17000	0.00720	0.06070	0.2609	0.0173	0.1388	34
IRSHAD	0.14100	0.04040	0.14500	0.2208	0.0552	0.2819	57
ONCOTYPEDX	0.05380	0.15600	0.20600	0.1126	0.1846	0.3586	25
SHARMA	0.46600	0.29700	0.60400	0.5489	0.3234	0.7237	58

Left columns: Comparative TMCC11 and known PCa signatures prognostic potential. Performance scored by log-rank test p-value of the difference on time to BCR between high and low risk groups defined by the overall gene expression signature. Right columns: Comparative analysis for TMCC11 and known PCa signatures over performance against random signatures. For each signature, 10,000 equal size signatures were generated at random and evaluated for predicting early relapse by log-rank test p-value. An overall bootstrap p-value score was computed as proportion of random signatures performing better than the initial signature. For both analyses, the data is sorted by first principal component of the individual rankings of the 3 columns corresponding to the Cambridge, Stockholm and MSKCC datasets. The Ross (100E) signature corresponds to the genes selected based on transcriptome profiling only. See also Additional file 1: Tables S5 and S6 for a full list with additional signatures

ISSN: 1471-2407